This study examined the cardiovascular safety of oral minoxidil, used off-label for androgenetic alopecia, particularly as its usage expands in real-world settings, although specific results were not detailed in the abstract.
This study evaluated the use of AI software SwissADME to compare Minoxidil and Sildenafil for alopecia treatment, finding Minoxidil to be more effective and safer, while highlighting limited potential for Sildenafil and emphasizing AI's role in optimizing drug development.
27 citations
,
November 2013 in “Dermatologic Therapy” This study suggests that a hair follicle enzyme assay may predict response to minoxidil treatment for androgenetic alopecia with high sensitivity and specificity in a preliminary analysis.
February 2016 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” A hair test can accurately predict if a person with hair loss will respond to minoxidil treatment.
In this descriptive retrospective study, researchers reported that low-dose oral minoxidil (0.25-5mg/day) for androgenic alopecia demonstrated a good safety profile, with 84.4% of 641 patients experiencing no adverse effects and only 1.4% discontinuing due to side effects that resolved with dose reduction or withdrawal.